title: [Efficacy of GLIDE chemotherapy for patients with newly diagnosed advanced-stage or relapsed/refractory extranodal natural killer cell lymphoma].
abstract: Objective:To evaluate the efficacy of gemcitabine, asparaginase , ifosfamide, dexamethasone and etoposide (GLIDE) combination for patients with newly diagnosed advanced-stage or relapsed/refractory extranodal natural killer cell lymphoma (ENKL).Methods:Fourty-two newly diagnosed advanced-stage or relapsed/refractory ENKL were enrolled from March 2010 to March 2016. Patients were treated with GLIDE for median 3 (2-6) cycles. Complete response (CR) rate, early CR (after 2 cycles) rate were evaluated after all treatment finished. Progression free survival (PFS) and overall survival (OS) were analyzed by Kaplan-Meier method and multivariate by Cox proportional hazards models.Results:Thirty-one (73.8%) patients achieved CR with 22 (52.4%) in early CR after 2 cycles of GLIDE, and 14 underwent autologous stem cell transplantation (ASCT) after achieved CR. One year PFS and OS were 65.6% and 82.7%, 4 year PFS and OS were 48.2% and 63.1%, respectively, with a median PFS of 30.5 months. Multivariate analysis indicated ECOG score 0-1 and ASCT after CR were independent prognostic factors for less relapse and longer survival.Conclusion:GLIDE is an effective regiment for newly diagnosed advanced-stage and relapsed/refractory ENKL.
authors.affiliation: Department of Hematology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China.
authors.forename: J
authors.initials: J
authors.lastname: Ji
authors.forename: B
authors.initials: B
authors.lastname: Xiang
authors.forename: Z G
authors.initials: ZG
authors.lastname: Liu
authors.forename: Y Q
authors.initials: YQ
authors.lastname: Jia
authors.forename: H L
authors.initials: HL
authors.lastname: Zhu
authors.forename: T
authors.initials: T
authors.lastname: Niu
authors.forename: L
authors.initials: L
authors.lastname: Pan
authors.forename: H
authors.initials: H
authors.lastname: Chang
authors.forename: J
authors.initials: J
authors.lastname: Huang
authors.forename: Y
authors.initials: Y
authors.lastname: Wu
authors.forename: J J
authors.initials: JJ
authors.lastname: Li
authors.forename: C
authors.initials: C
authors.lastname: He
authors.forename: H B
authors.initials: HB
authors.lastname: Ma
authors.forename: Y
authors.initials: Y
authors.lastname: Tang
authors.forename: T
authors.initials: T
authors.lastname: Dong
authors.forename: T
authors.initials: T
authors.lastname: Liu
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001215:Asparaginase / Q000008:administration & dosage; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D003907:Dexamethasone / Q000008:administration & dosage; D018572:Disease-Free Survival; D005047:Etoposide / Q000008:administration & dosage; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D007694:Killer Cells, Natural; D008223:Lymphoma / Q000188:drug therapy*; D012008:Recurrence; D012074:Remission Induction; D000093542:Gemcitabine
chemical_list: D003841:Deoxycytidine; D005047:Etoposide; D003907:Dexamethasone; D001215:Asparaginase; D007069:Ifosfamide; D000093542:Gemcitabine